Arcadia Investment Management Corp MI Has $1.39 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Arcadia Investment Management Corp MI raised its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 9.8% in the third quarter, HoldingsChannel.com reports. The fund owned 38,614 shares of the company’s stock after purchasing an additional 3,439 shares during the quarter. Arcadia Investment Management Corp MI’s holdings in Dyne Therapeutics were worth $1,387,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of DYN. Nisa Investment Advisors LLC lifted its stake in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after buying an additional 669 shares during the last quarter. US Bancorp DE lifted its stake in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after buying an additional 1,212 shares during the last quarter. Values First Advisors Inc. acquired a new stake in shares of Dyne Therapeutics during the 3rd quarter worth about $62,000. Amalgamated Bank lifted its stake in shares of Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after buying an additional 796 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Dyne Therapeutics by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after buying an additional 709 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Insider Activity at Dyne Therapeutics

In related news, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the sale, the director now directly owns 234,127 shares of the company’s stock, valued at approximately $8,533,929.15. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Dyne Therapeutics news, CEO John Cox bought 32,000 shares of Dyne Therapeutics stock in a transaction on Wednesday, September 4th. The shares were purchased at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the acquisition, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at $264,320. The trade was a -100.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Dirk Kersten sold 79,411 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the sale, the director now directly owns 234,127 shares in the company, valued at $8,533,929.15. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 158,975 shares of company stock valued at $5,693,789. 20.77% of the stock is owned by insiders.

Dyne Therapeutics Price Performance

DYN stock opened at $28.74 on Friday. Dyne Therapeutics, Inc. has a 12 month low of $7.09 and a 12 month high of $47.45. The company’s 50-day moving average price is $34.65 and its two-hundred day moving average price is $34.76.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, sell-side analysts expect that Dyne Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Guggenheim lifted their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. Morgan Stanley lifted their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Oppenheimer reiterated an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Finally, Stifel Nicolaus lifted their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.60.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.